Inventor · disambiguated record
David Campbell
Also filed as: CAMPBELL DAVID · CAMPBELL DAVID A · CAMPBELL DAVID ANDREW
11 granted patents·28 pending applications·74 citations·filing 1984–2025
87Inventor score
Files withJANUX THERAPEUTICS INC28RQX PHARMACEUTICALS INC5BURROUGHS WELLCOME CO1INST SYSTEMS BIOLOGY1MEDICAL RES COUNCIL1
Top patents by PatentIndex Score
39 records- 0194US11512113B2Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Granted Nov 29, 2022·7 cites·25 claims
- 0288US12161724B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·1 cites·21 claims
- 0383US4693893AVaccines for equine influenzaBURROUGHS WELLCOME CO·Filed 1984·Granted Sep 15, 1987·45 cites·4 claims
- 0482US10501493B2Broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2016·Granted Dec 10, 2019·2 cites·19 claims
- 0581US9309285B2Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2013·Granted Apr 12, 2016·4 cites·16 claims
- 0681US8999922B2Linear peptide antibioticsRQX PHARMACEUTICALS INC·Filed 2013·Granted Apr 7, 2015·3 cites·25 claims
- 0780US12433953B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2024·Granted Oct 7, 2025·0 cites·31 claims
- 0878US2024376226A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0978US2025019403A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1072US2023348618A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1171US2023147782A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1270US11555078B2Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Granted Jan 17, 2023·0 cites·26 claims
- 1370US2023270854A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1467US2010047823A1PolypeptidesMEDICAL RES COUNCIL·Filed 2009·Application pending·0 cites
- 1562US2023220105A1Tumor activated t cell engagers and methods of use thereofJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1662US2023220109A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1761US2023357429A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1861US2023357447A1Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1960US2025154278A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2060US2024059790A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2158US2024254241A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2258US2018339043A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2356US9708368B2Linear peptide antibioticsRQX PHARMACEUTICALS INC·Filed 2015·Granted Jul 18, 2017·0 cites·19 claims
- 2456US2024034814A1Half-life extending compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2555US2024043536A1Peptide compositions and methods for anti-cd3 binding domainsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2655US2024034806A1Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2754US2023406955A1Antibodies targeting her2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2854US2021115106A1Modified t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2954US2024092931A1Antibodies targeting trop2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3054US2024043565A1Antibodies targeting psma and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3154US2023406937A1Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3254US2020385440A1Modified bispecific t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3351US2025250339A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3451US2017275334A1Linear peptide antibioticsRQX PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3549US2025297017A1Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3648US6045790AVaccines for equine influenzaFiled 1992·Granted Apr 4, 2000·12 cites·11 claims
- 3745US2004106148A1PolypeptidesFiled 2001·Application pending·0 cites
- 3841US2014249073A1Broad spectrum antibioticsROBERTS TUCKER CURRAN·Filed 2012·Application pending·0 cites
- 3935US9726667B2Point of care assays to detect the status of tuberculosis infectionINST SYSTEMS BIOLOGY·Filed 2015·Granted Aug 8, 2017·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when David Campbell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →